Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients

11 Jun 2021

Abstract excerpt

Resistance to drug treatments is common in prostate cancer (PCa), and the gain-of-function mutations in human androgen receptor (AR) represent one of the most dominant drivers of progression to resistance to AR pathway inhibitors (ARPI). Previously, we evaluated the in vitro response of 24 AR mutations, identified in men with castration-resistant PCa, to five AR antagonists. In the current work, we evaluated 44...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Hormonal and reproductive studies
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34208290
DOI: 10.3390/cancers13122939

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer PatientsPMID 34208290Read ↗

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity Read ↗

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Androgen receptor gene mutation, rearrangement, polymorphism.Semantic proximity Read ↗

Deep Modeling of Gain-of-Function Mutations on Androgen ReceptorSemantic proximity Read ↗

Androgen receptor mutations for precision medicine in prostate cancer.Semantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Androgen receptor plasticity and its implications for prostate cancer therapy.Semantic proximity Read ↗

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read ↗

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies.Semantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

Deep Learning Modelling of Androgen Receptor Responses to Prostate Cancer TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.